aTyr Pharma Inc.

162 articles with aTyr Pharma Inc.

• aTyr Pharma to Host Virtual Key Opinion Leader Event on Current Treatment Options for Pulmonary Sarcoidosis

  6/23/2021

  aTyr Pharma, Inc. today announced that the company will host a virtual Key Opinion Leader (KOL) event on the current treatment options for pulmonary sarcoidosis on Tuesday, June 29th at 5:00pm ET/2:00pm PT.

• aTyr Pharma Presents Poster Demonstrating Functional Selectivity of Second Anti-NRP2 Antibody

  6/10/2021

  aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the presentation of a poster at the Antibody Engineering & Therapeutics Europe Virtual conference which was held June 8 – 10, 2021

• Kezar Life Sciences Announces Formation of Clinical Advisory Committee

  6/8/2021

  Kezar Life Sciences, Inc., a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, announced the formation of its Clinical Advisory Committee.

• aTyr Pharma Strengthens Board of Directors with Appointment of Dr. Sara Zaknoen

  5/25/2021

  aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, announced the appointment of Sara Zaknoen, M.D., to the company’s Board of Directors.

• aTyr Pharma Presents Preclinical Research Highlighting Mechanistic Insights into Tumor Inhibitory Effects of ATYR2810

  5/19/2021

  aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will present a poster and participate in a live Q&A session at the Virtual Keystone Symposia on Cancer Stem Cells: Advances in Biology and Clinical Translation , which is being held May 19 – 21, 2021.

• aTyr Pharma Announces First Quarter 2021 Results and Provides Corporate Update

  5/13/2021

  aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced first quarter 2021 results and provided a corporate update

• aTyr Pharma and its Hong Kong Subsidiary, Pangu BioPharma, Achieve Milestones for First Year of Government Grant to Develop Bispecific Antibody Platform

  5/12/2021

  Two-year grant awarded by the Hong Kong Government’s Innovation and Technology Commission is funding the development of new bispecific antibodies targeting NRP2

• aTyr Pharma Announces Promotion of Leslie Nangle, Ph.D., to Vice President of Research

  5/11/2021

  aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, announced the promotion of Leslie Nangle, Ph.D., to Vice President, Research.

• aTyr Pharma to Webcast Conference Call Reporting First Quarter 2021 Financial ResultsManagement to host conference call and webcast on May 13th at 5:00 pm EDT / 2:00 pm PDT

  5/6/2021

  aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will report first quarter 2021 financial results and provide a corporate update after the market close on Thursday, May 13, 2021. Management will host a conference call and webcast to review the results and provide an operational update.

• aTyr Pharma and Lonza Announce Manufacturing Agreement for aTyr’s Anti-NRP2 Antibody ATYR2810

  4/14/2021

  aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, and Lonza today announced that the companies have entered into an agreement for the manufacture of ATYR2810, aTyr’s monoclonal antibody targeting Neuropilin-2 (NRP2) that is currently in preclinical development for cancer.

• aTyr Pharma Presents Preclinical Research Showing Effects of ATYR2810 in Lung and Breast Cancer at the 2021 AACR Virtual Annual Meeting

  4/9/2021

  Findings demonstrate tumor inhibitory effects of ATYR2810 when used as a monotherapy or in combination with chemotherapy in models of non-small cell lung cancer. ATYR2810 used in combination with chemotherapy or bevacizumab increased anti-tumor effects in triple-negative breast cancer model.

• aTyr Pharma Announces Co-Founder of the Foundation for Sarcoidosis Research and Leading Sarcoidosis Advocate Andrea Wilson as Patient Advisor

  4/8/2021

  aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the appointment of Andrea Wilson as a patient advisor to the company. Ms. Wilson, a sarcoidosis patient and advocate, co-founded the Foundation for Sarcoidosis Research (FSR), the leading international nonprofit organization dedicated to finding a cure for sarcoidosis and im

• aTyr Pharma Announces Fourth Quarter and Full Year 2020 Results and Provides Corporate Update

  3/23/2021

  aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced fourth quarter and full year 2020 results and provided a corporate update.

• aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2020 Financial ResultsManagement to host conference call and webcast on March 23rd at 5:00 pm EDT / 2:00 pm PDT

  3/16/2021

  aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will report fourth quarter and full year 2020 financial results and provide a corporate update after the market close on Tuesday, March 23, 2021.

• aTyr Pharma Announces Positive Biomarker Data from Phase 2 Clinical Trial of ATYR1923 Demonstrating Anti-Inflammatory Effects in COVID-19 Patients with Severe Respiratory Complications

  3/15/2021

  aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced biomarker results from its Phase 2 double-blind, placebo-controlled clinical trial of its lead therapeutic candidate, ATYR1923, in hospitalized COVID-19 patients with severe respiratory complications receiving standard of care, including remdesivir and/or dexamethasone,

• aTyr Pharma Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting

  3/11/2021

  aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company will present two posters at the upcoming American Association for Cancer Research (AACR) Annual Meeting, which is being held virtually April 10 – 15 and May 17 – 21.

• Leading Cancer Researcher Dr. Judith Varner Joins aTyr Pharma as Scientific AdvisorDr. Varner to advise company on mechanistic understanding of Neuropilin-2 (NRP2) and the development of novel anti-NRP2 antibody therapeutics for cancer

  3/10/2021

  aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the appointment of Judith Varner, Ph.D., as a scientific advisor to the company. Dr. Varner currently serves as Professor in the Departments of Pathology and Medicine at the Moores Cancer Center at the University of California, San Diego (UCSD).

• aTyr Pharma to Present at March Investor Conferences

  2/25/2021

  aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will present at four virtual investor conferences in March.

• aTyr Pharma Announces New tRNA Synthetase Discovery Programs

  2/11/2021

  aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it has initiated two new discovery programs from its tRNA synthetase platform

• aTyr Pharma to Present at BIO CEO & Investor Digital Conference

  2/9/2021

  aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present a corporate overview at the BIO CEO & Investor Digital Conference, which is being held February 16 – 18, 2021.